Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016

Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016
Published Jun 30, 2016
44 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016, provides in depth analysis on Hepatitis B Virus Core Antigen (HBcAg) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatitis B Virus Core Antigen (HBcAg), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatitis B Virus Core Antigen (HBcAg)
- The report reviews Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis B Virus Core Antigen (HBcAg)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by un

  
Source:
Document ID
GMDHC0319TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Hepatitis B Virus Core Antigen (HBcAg) Overview61
Therapeutics Development73
  Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Stage of Development71
  Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Therapy Area81
  Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Indication91
Hepatitis B Virus Core Antigen (HBcAg) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Companies122
Hepatitis B Virus Core Antigen (HBcAg) Therapeutics Assessment144
  Assessment by Monotherapy/Combination Products141
  Assessment by Route of Administration151
  Assessment by Molecule Type162
Hepatitis B Virus Core Antigen (HBcAg) Companies Involved in Therapeutics Development185
  Abivax S.A.181
  F. Hoffmann-La Roche Ltd.191
  Gilead Sciences, Inc.201
  Transgene SA211
  VLP Biotech, Inc.221
Hepatitis B Virus Core Antigen (HBcAg) Drug Profiles238
  ABX-203 Drug Profile231
  GS-4774 Drug Profile242
  hepatitis B vaccine Drug Profile261
  RG-7944 Drug Profile272
  TG-1050 Drug Profile292
Hepatitis B Virus Core Antigen (HBcAg) Dormant Projects311
Hepatitis B Virus Core Antigen (HBcAg) Featured News &Press Releases3211
  Dec 08, 2015: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B321
  Nov 04, 2015: Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection331
  May 27, 2015: GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients331
  Apr 23, 2015: Transgene Presents New Data with TG1050, an Immunotherapy Being Developed to Treat Chronic Hepatitis B, at The International Liver Congress 2015341
  Apr 21, 2015: Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection341
  Feb 26, 2015: ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B351
  Jul 01, 2014: Transgene Announces Presentation of Data on TG1050 Immunotherapy against Chronic Hepatitis B361
  Nov 05, 2013: Transgene Announces Data on TG1050 Presented at Recent Medical and Scientific Conferences361
  Apr 29, 2013: Transgene Presents Positive Preclinical Data On TG1050 To Treat Chronic HBV At EASL 2013371
  Apr 08, 2013: Transgene To Present New Data On TG1050 To Treat Chronic Hepatitis B At EASL 2013 Conference381
  Jan 28, 2013: GlobeImmune Initiates Phase Ia Clinical Trial Of GI-13020 In Healthy Volunteers381
  Nov 12, 2012: Inovio Pharma's Hepatitis B Vaccine Demonstrates Potential To Clear Hepatitis B Virus In Liver In Preclinical Study391
  Nov 12, 2012: Inovio Pharma's Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential To Clear HBV In Liver391
  Apr 19, 2012: Transgene s New Therapeutic Vaccine Candidate to Treat Chronic Hepatitis B Reaches Preclinical Proof of Concept401
  Oct 10, 2011: Inovio Pharma And VGX International To Advance Therapeutic Hepatitis C And Hepatitis B Synthetic Vaccines Into Clinical Studies412
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepatitis-B-Virus-Core-Antigen-HBcAg-Pipeline-Review-H1-2016-2088-16142>
  
APA:
Global Markets Direct - Market Research. (2016). Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepatitis-B-Virus-Core-Antigen-HBcAg-Pipeline-Review-H1-2016-2088-16142>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.